CDMO MedPharm has announced that it will provide formulation and delivery development services for Swiss startup Mosanna Therapeutics’ MOS-118 potassium channel blocker, with the goal of advancing a nasal spray formulation into clinical development for the treatment of metabolic obstructive sleep apnea (MOSA). Mosanna was formed recently to develop MOS-118 (formerly AVE-0118), which was initially developed by Sanofi.
MedPharm President and CEO Eugene Ciolfi said, “MedPharm’s primary mission is to support the development of life-changing therapeutics, and Mosanna’s nasal spray is a promising opportunity to do just that. We are excited to work with their team of experienced industry leaders to realize MOS-118’s potential with the end goal of improving the quality of life for those living with metabolic obstructive sleep apnea.”
Mosanna CEO Jonathan Talbot commented, “MedPharm is world-renowned for its dermal and transdermal capabilities including intranasal delivery routes so was a clear first choice for this project. I am also excited by the potential this partnership creates for additional projects on the horizon for Mosanna.”
Read the MedPharm press release.
